Search research articles
Contact Us
Filters
Showing results (501-510 of 525) with videos related to
Page
of 53
Sort By:
Journal of Clinical Immunology
|
January 7, 2021
Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study
John T Anderson, Vincent R Bonagura, Juthaporn Cowan, et al.
Molecular Cancer Therapeutics
|
February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
Ulrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
Science Signaling
|
November 25, 2025
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i>-mutant lung cancer
Brianna R Daley, Patricia L Theard, Jacob M Hughes, et al.
Molecular Cancer Therapeutics
|
October 7, 2015
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis
Michael P Sanderson, Joshua Apgar, Pilar Garin-Chesa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 27, 2023
Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage
Mark Jackson, Niousha Ahmari, Jianqiang Wu, et al.
Molecular Cancer Therapeutics
|
July 22, 2017
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy
Michael P Sanderson, Marco H Hofmann, Pilar Garin-Chesa, et al.
Rheumatology (Oxford, England)
|
February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis
Christopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 14, 2022
Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition
Irmgard Hofmann, Anke Baum, Marco H Hofmann, et al.
Journal of Medicinal Chemistry
|
July 14, 2023
Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer
Christian A Kuttruff, Martin Fleck, Sebastian Carotta, et al.
The Journal of Biological Chemistry
|
December 5, 1998
Anti-pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase
H M Bömmel, A Reif, L G Fröhlich, et al.
Page
of 53
Search research articles
Search
Showing results (501-510 of 525) with videos related to
Sort By:
Page
of 53
Journal of Clinical Immunology
|
January 7, 2021
Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study
John T Anderson, Vincent R Bonagura, Juthaporn Cowan, et al.
Molecular Cancer Therapeutics
|
February 15, 2020
Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
Ulrike Weyer-Czernilofsky, Marco H Hofmann, Katrin Friedbichler, et al.
Science Signaling
|
November 25, 2025
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i>-mutant lung cancer
Brianna R Daley, Patricia L Theard, Jacob M Hughes, et al.
Molecular Cancer Therapeutics
|
October 7, 2015
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis
Michael P Sanderson, Joshua Apgar, Pilar Garin-Chesa, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 27, 2023
Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage
Mark Jackson, Niousha Ahmari, Jianqiang Wu, et al.
Molecular Cancer Therapeutics
|
July 22, 2017
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy
Michael P Sanderson, Marco H Hofmann, Pilar Garin-Chesa, et al.
Rheumatology (Oxford, England)
|
February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis
Christopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 14, 2022
Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition
Irmgard Hofmann, Anke Baum, Marco H Hofmann, et al.
Journal of Medicinal Chemistry
|
July 14, 2023
Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer
Christian A Kuttruff, Martin Fleck, Sebastian Carotta, et al.
The Journal of Biological Chemistry
|
December 5, 1998
Anti-pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase
H M Bömmel, A Reif, L G Fröhlich, et al.
Page
of 53